Résumé de communication

Objectives: Learning Objectives Upon completion of this presentation, participants will be able to: 1. Demonstrate the anatomical landmarks and injection techniques for safe and effective gluteal botulinum toxin type A (BoNT-A) administration (Skill-based). 2. Evaluate patient candidacy for gluteal BoNT-A lifting by analyzing indications/contraindications and comparing outcomes with alternative procedures (Clinical decision-making). 3. Implement evidence-based BoNT-A dosing protocols (50–100 U per side) to achieve predictable contouring while minimizing adverse effects (Practical application) Introduction: The growing demand for minimally invasive gluteal enhancement procedures necessitates exploration of innovative techniques. While botulinum toxin type A (BoNT-A) is well-established for facial wrinkles and hyperhidrosis, its potential for gluteal remodeling remains understudied. Materials / method: This study enrolled 16 patients presenting with mild gluteal ptosis or asymmetry. Intramuscular injections of botulinum toxin type A (50-100 units per side) were administered into the gluteus maximus muscle using a standardized quadrant injection protocol. Outcomes were assessed at 1-, 4-, 6-month follow-ups utilizing: - Standardized photographic documentation - Global Aesthetic Improvement Scale (GAIS) - Gluteal projection angle measurements (lateral view analysis) Results: The study demonstrated significant clinical outcomes: - 93.75% (n=15/16) of patients exhibited measurable improvement in gluteal contour with mild lifting effect (p<0.01) - Mean effect duration: 4.5 months (±0.7 months) - Adverse events: - Transient muscle weakness: 6.25% (n=1) - No cases of gait disturbance or severe complications - Patient-reported outcomes: - 81.3% satisfaction rate (GAIS ≥3) - Significant improvement in body image perception (p=0.02). Conclusion: This pilot study demonstrates that botulinum toxin type A (BoNT-A) represents a promising minimally invasive approach for gluteal contouring, particularly in patients with: - Mild-to-moderate ptosis (Grade I-II) - Muscular asymmetry (≤20% volume discrepancy)